- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Science
- Onco-Metabolism Platform
- Therapeutic Areas
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor Telaglenastat
- Arginase Inhibitor INCB001158
- Arginase Inhibitor
CB-280 - CD73 Inhibitor
CB-708 - Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Science
Publications and Presentations
Check out our publications and poster presentations.
April 2014
Novel Pharmacodynamic Assays to Measure Glutaminase Inhibition Following Oral Administration of CB-839 (Parlati, et al.) CB-839, a Novel Potent and Selective Glutaminase Inhibitor, has Broad Antiproliferative Activity in Cell lines Derived from Both Solid Tumors and Hematologic Malignancies (Parlati, et al.)American Association of Cancer Research – April 2014
December 2013
Antitumor Activity of the Glutaminase Inhibitor, CB-839, in Triple-Negative Breast Cancer (Gross, et al.)San Antonio Breast Cancer Symposium
December 2013
Antitumor Activity of Glutaminase Inhibitor CB-839 in Hematological Tumors (Parlati, et al.)American Society of Hematology
April 2013
Anti-Tumor Activity of Novel, Potent and Orally-Bioavailable Glutaminase inhibitorAmerican Association of Cancer Research – 2013
Our Pipeline
We are focused on novel treatments for
cancer and other life-threatening diseases.